Beware of Selling Pressure on Roblox, CoreWeave, and The Trade Desk
The gaming sector has obvious winners that include Electronic Arts (EA) and Take-Two Interactive (TTWO). Roblox (RBLX), whose stock peaked at $150.59, is a less obvious choice. Shares more than doubled their price from the $50 low in April to close at $117.34. Last Friday, RBLX stock lost 6.34% on multiple reports that the platform did not protect child-aged gamers against child predators. NBC News reported that the attorney general in Louisiana filed a suit. It accused the firm of lacking strong safety protocols. RBLX stock has a short interest of 2.81%. Few bears are betting against the gaming platform.CoreWeave (CRWV) recently rallied to around $150 only to slump. It closed at $99.97 on Aug. 15. The lockup period ended last week. The chances are high that insiders will file sales in the AI hyperscaler firm. Already, Jack Cogen, a director, has sold around $300 million worth of shares. Investors should consider Nebius Group (NBIS) instead for better relative value.Shorts circulated a rumor that The Trade Desk (TTD) lost Walmart’s (WMT) business. TTD posted a press release to refute the claim. Still, the $60-$80 uptrend this summer is over. TTD stock closed at $52.12 on Aug. 15. Selling pressure will continue, since TTD cannot publicize too many details on the Walmart advertising strategy. That would help competitors like Costco (COST) and Target (TGT). As a result, it could push the share price below $50.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


